| Name | Title | Contact Details |
|---|
Viral Sensitizers (VSE) for drug developers and manufacturers are small molecules that improve viral yields and effectiveness by reducing the antiviral defences on a cellular level.
Mavupharma is developing non-nucleotide, conditional modulators of the STING pathway to treat cancer and infectious disease.
Viracta is focused on advancing a proprietary viral gene activation therapy to address cancers associated with the Epstein-Barr Virus, and will pursue opportunities to address other serious virus-associated disease.
Ensysce Biosciences, San Diego, CA, is a clinical stage private biopharma with prodrug platforms that address opioid use disorder. Trypsin-Activated Abuse Protection (TAAP) technology forms an opioid prodrug that can only be activated through a 2-step internal digestive process, and therefore cannot be abused by chewing, snorting or IV administration.
FirstLight Health Systems is a Mora, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.